Evidence map›Paper›PMID 37869030›Full record

ArticleOphthalmology science

Macular Sensitivity Endpoints in Geographic Atrophy: Exploratory Analysis of Chroma and Spectri Clinical Trials.

Dolly S Chang, Natalia F Callaway, Verena Steffen, Karl Csaky, Robyn H Guymer, David G Birch, Praveen J Patel, Michael Ip, Simon S Gao, Jayla Briggs and 4 more

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02247479 phase3terminatednot on this map

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

TypeinterventionalSponsorHoffmann-La RocheRan2014 to 2018Enrolled906ConditionsGeographic AtrophyArmsLampalizumab, Sham
NCT02247531 phase3terminatednot on this map

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

TypeinterventionalSponsorHoffmann-La RocheRan2014 to 2018Enrolled975ConditionsGeographic AtrophyArmsLampalizumab, Sham Comparator
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Visual Function Assessment in Geographic Atrophy: A Review.Clinical & experimental ophthalmology · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Dolly S ChangGenentech, Inc., South San Francisco, California.
Natalia F CallawayGenentech, Inc., South San Francisco, California.
Verena SteffenGenentech, Inc., South San Francisco, California.
Karl CsakyRetina Foundation of the Southwest, Dallas, Texas.
Robyn H GuymerCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Australia.
David G BirchRetina Foundation of the Southwest, Dallas, Texas.
Praveen J PatelNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom.
Michael IpDoheny Eye Institute, University of California, Los Angeles, California.
Simon S GaoGenentech, Inc., South San Francisco, California.
Jayla BriggsGenentech, Inc., South San Francisco, California.
Lee HonigbergGenentech, Inc., South San Francisco, California.
Phillip LaiGenentech, Inc., South San Francisco, California.
Daniela FerraraGenentech, Inc., South San Francisco, California.
Yasir J SepahByers Eye Institute, Stanford University School of Medicine, Palo Alto, California.
Smith-Kettlewell Eye Research Institute · USRetina Foundation of the Southwest · USMoorfields Eye Hospital NHS Foundation Trust · GBThe University of Melbourne · AUUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To assess different microperimetry (MP) macular sensitivity outcome measures capturing functional deterioration in eyes with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Design: Patients were included from 2 identically designed, phase III, double-masked, randomized controlled clinical trials, Chroma (NCT02247479) and Spectri (NCT02247531). Participants: Patients enrolled were aged ≥ 50 years with bilateral GA and no evidence of previous or active neovascular AMD. Methods: Patients were randomized 2:1:2:1 to receive through 96 weeks intravitreal lampalizumab 10 mg every 4 weeks (LQ4W), every 6 weeks (LQ6W), or corresponding sham procedures. For this study, mesopic macular sensitivity of the central 20° was assessed using MP-1 microperimeter at selected sites. Main Outcome Measures: Two exploratory endpoints were developed, namely perilesional sensitivity (average of points adjacent to absolute scotomatous points) and responding sensitivity (average of all nonscotomatous points; > 0 dB at baseline) by using customized masks for each patient. These were compared with conventional MP endpoints (mean macular sensitivity and number of absolute scotomatous points). Results: Of 1881 Chroma and Spectri participants, 277 agreed to participate in the present study. Of these, 197 (LQ4W, n = 63; LQ6W, n = 68; pooled sham, n = 66) had reliable MP results. Enlargement of GA lesion area by approximately 2 mm Conclusions: Perilesional or responding macular sensitivity measured by MP should be considered more sensitive endpoints than mean macular sensitivity for monitoring functional decline over time in GA. Although perilesional, responding, and mean macular sensitivity had weak correlation with GA lesion area, the number of absolute scotomatous points may provide additional information on the anatomic/functional correlation. Financial Disclosures: Proprietary or commercial disclosure may be found after the references.

Indexed as

Geographic atrophyMesopic microperimetryPerilesional sensitivityResponding sensitivityVisual function

Identifiers

PMID37869030
PMCPMC10587617
OpenAlexW4380355348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.